uniQure NV (LTS:0EE0)
$ 16.2348 0.9948 (6.53%) Market Cap: 762.83 Mil Enterprise Value: 395.19 Mil PE Ratio: 0 PB Ratio: 14.23 GF Score: 63/100

uniQure N.V. - Special Call Transcript

Jun 24, 2020 / 09:30PM GMT
Release Date Price: $63.58
Maria E. Cantor
uniQure N.V. - SVP of IR & Communication

Good afternoon, and thank you for joining us. After market closed today, we issued a press release announcing a major licensing agreement with CSL Behring for rights to our hemophilia B gene therapy program. This press release is available on the Investor page of our corporate website, uniqure.com, along with an accompanying slide deck.

Joining me to discuss the significant business update are Matt Kapusta, Chief Executive Officer of uniQure; and Jon Garen, Chief Business Officer. After our formal remarks, we will open the call to our research analysts for Q&A.

During this call, please note that we will be making forward-looking statements. These statements will be subject to factors, risks and uncertainties, including those that are detailed in our Form 10-Q for the period ended March 31, 2020, as well as subsequent SEC filings that may cause actual results to differ materially from those that are expressed or implied by such statements.

Now it's my pleasure to hand over the call to Matt for opening remarks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot